CBD targeted as "prime candidate" in new Alzheimer's treatment strategy

enfleur-blog-alzheimers-cbd.jpg
ENFLEUR 1000mg Broad Spectrum Cannabinoids
Quick View
ENFLEUR 1000mg Broad Spectrum Cannabinoids
65.00
Quantity:
Add To Cart
ENFLEUR 1000mg Full Spectrum Cannabinoids
65.00
Quantity:
Add To Cart

ENFLEUR is gratified to share a review published by the rigorously peer-reviewed journal Frontiers in Pharmacology concluding that the evidence in its selected studies provide “proof of principle” in terms of the therapeutic benefits of CBD in Alzheimer’s. Noting that current Alzheimer’s treatments are accompanied by a number of unwanted side-effects, such as nausea, vomiting, diarrhea, hallucinations, fatigue, and dizziness, the study goes on to point out that none of these available treatments are able to reverse or prevent Alzheimer’s. Therefore, a need for developing a multi-functional compound that addresses a variety of Alzheimer’s symptoms simultaneously is indicated, the review identifies CBD as the prime candidate for this treatment strategy. Taking this, as well as CBD’s neuroprotective activity into consideration, makes adding a quality CBD product into a daily wellness regime a worthwhile consideration.

Why does this matter? CBD has been identified as a prime candidate in a new treatment strategy for Alzheimer’s disease.